To Top

Pipeline

Overview

Multiple links image

CM24NT219

CM24

CM24 is a first-in-class clinical stage mAb targeting CEACAM1, a novel immune checkpoint inhibitor with significant potential to treat multiple cancers.

Read More

NT219

NT219 is a first-in-class, novel small molecule targeting both IRS1/2 and STAT3, important oncogenic drivers and major drug resistance pathways in many hard-to-treat cancers.

Read More

Publications

NT219

October 25, 2021

IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy

Published in Nature Cancer, October 2021

View >
June 6, 2021

A Phase 1 2 Study with Open Label, Dose Escalation Phase Followed by Single Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT 219 Injection Alone and in Combination with Cetuximab in Adults with Advanced Solid Tumors and Head and Neck Cancer

Presented at ASCO annual meeting 2021

View >
April 12, 2021

Adaptation of Colorectal Cancer Cells to the Brain Microenvironment The Role of IRS2

Presented at the AACR annual meeting 2021

View >
April 1, 2020

NT219, a Novel Dual Inhibitor of STAT3 and IRS1/2, Demonstrates Anti-Tumor Activity With and Without Cetuximab in Pembrolizumab-Resistant Head and Neck Cancer PDX Models

Presented at the AACR annual meeting 2020

View >
February 1, 2020

A phase I/II, Open-label, Dose Escalation Followed by Single-arm Expansion to Assess the Safety and Efficacy of NT219 in Combination with Cetuximab in Patients with R/M HNSCC

Presented at the 2020 multidisciplinary Head and Neck Cancers Symposium

View >
April 1, 2019

NT219, A Novel Bi-specific Inhibitor of STAT3 and IRS1/2, Combined with Chemotherapy or MEK Inhibitor in Gemcitabine-Resistant Pancreatic Tumors, Induced Tumor Regression

Presented at the 2019 AACR Special Conference Pancreatic Cancer

View >
April 1, 2018

NT219, A Novel Dual Inhibitor of STAT3 and IRS1/2, Converts Immuno-Oncology Resistant Tumors to Responders

Presented at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy

View >
April 1, 2017

Comprehensive high throughput screen for combination therapies to block acquired resistance to targeted drugs

Presented at the AACR annual meeting 2017

View >

CM24

April 11, 2022

Interim Safety and Efficacy Results from a Phase 1b Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

Presented at the AACR annual meeting April, 2022

View >
September 29, 2021

A Phase 1b Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors, followed by a Phase 2a study of CM24 in Combination with Nivolumab in NSCLC, and in Combination with Nivolumab and nab-paclitaxel in Pancreatic Cancer

Presented at the ESMO annual meeting 2021

View >
May 1, 2020

A Phase 1 Open-label Multicenter Single Dose Escalation and Multi-dose Study of a mAb Targeting CEACAM1 in Subjects with Selected Advanced or Recurrent Malignancies

Presented at the ASCO annual meeting 2020

View >
Skip to content